Value of preoperative HE4 as predictor of advanced disease in endometrioid endometrial cancer
ABSTRACT Objective To explore the predictive value of serum human epididymis protein 4 (HE4) marker in the preoperative prediction of the risk of advanced disease in the endometrioid subtype of endometrial cancer, and its association with poor prognostic factors. In addition, a cut‐off value of HE4...
Gespeichert in:
| Veröffentlicht in: | International journal of gynecology and obstetrics 2021-04, Vol.153 (1), p.64-70 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 70 |
|---|---|
| container_issue | 1 |
| container_start_page | 64 |
| container_title | International journal of gynecology and obstetrics |
| container_volume | 153 |
| creator | Espiau Romera, Andrea Coronado Martín, Pluvio Jesús Chóliz Ezquerro, Marta Cuesta Guardiola, Tatiana Adiego Calvo, Ignacio Baquedano Mainar, Laura |
| description | ABSTRACT
Objective
To explore the predictive value of serum human epididymis protein 4 (HE4) marker in the preoperative prediction of the risk of advanced disease in the endometrioid subtype of endometrial cancer, and its association with poor prognostic factors. In addition, a cut‐off value of HE4 was defined to classify patients according to these results.
Methods
Prospective and multicenter cohort analytical pilot study of patients operated for endometrial cancer at the Miguel Servet University Hospital of Zaragoza (Spain) and the Complejo Universitario of León (Spain) from January 2017 to May 2019. Preoperative serum levels of HE4 were analyzed by clinical and pathologic characteristics.
Results
In all, 126 patients were included. A statistically significant association was found between the preoperative HE4 value and node involvement (P = 0.008), late‐stage disease (P = 0.003), high histologic grade (P = 0.007), deep myometrial invasion (P = 0.001), lymphovascular space invasion (P = 0.001), and other pathologic factors. In addition, an HE4 cut‐off value (156.4 pmol/L) has been determined to predict, preoperatively, which patients will present with early stage disease.
Conclusions
The preoperative marker HE4 is a useful tool in the preoperative study of patients with endometrial cancer as it relates to late‐stage disease as well as other prognostic factors in the endometrioid subtype of endometrial cancer.
High preoperative values of HE4, especially higher than 156.4 pmol/L, seem to be associated with an advanced stage of disease in endometrioid endometrial cancer. |
| doi_str_mv | 10.1002/ijgo.13473 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2458036211</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2458036211</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3293-1350736089d60e22b90954c01a0b1a362e7ee7164fce6fbcda88594de1602bdc3</originalsourceid><addsrcrecordid>eNp9kD1PwzAQQC0EoqWw8ANQRoSU4rPzOaKqtEWVugAbihz7glwlcbDTov57ElJgYzrf-ekNj5BroFOglN3r7buZAg9ifkLGkMSp373TUzLuPqkfs5SNyIVzW0opxADnZMQ5hFHI2Zi8vYpyh54pvMaiadCKVu_RW84DT7j-prRsje0Bofailqg8pR0Kh56uPayVqbC12mj1t4jSkz1qL8lZIUqHV8c5IS-P8-fZ0l9vFqvZw9qXnKXcBx7SmEc0SVVEkbE8pWkYSAqC5iB4xDBGjCEKColRkUslkiRMA4UQUZYrySfkdvA21nzs0LVZpZ3EshQ1mp3LWBAmtPMAdOjdgEprnLNYZI3VlbCHDGjW58z6nNl3zg6-OXp3eYXqF_3p1wEwAJ-6xMM_qmz1tNgM0i9SBn-t</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2458036211</pqid></control><display><type>article</type><title>Value of preoperative HE4 as predictor of advanced disease in endometrioid endometrial cancer</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Espiau Romera, Andrea ; Coronado Martín, Pluvio Jesús ; Chóliz Ezquerro, Marta ; Cuesta Guardiola, Tatiana ; Adiego Calvo, Ignacio ; Baquedano Mainar, Laura</creator><creatorcontrib>Espiau Romera, Andrea ; Coronado Martín, Pluvio Jesús ; Chóliz Ezquerro, Marta ; Cuesta Guardiola, Tatiana ; Adiego Calvo, Ignacio ; Baquedano Mainar, Laura</creatorcontrib><description>ABSTRACT
Objective
To explore the predictive value of serum human epididymis protein 4 (HE4) marker in the preoperative prediction of the risk of advanced disease in the endometrioid subtype of endometrial cancer, and its association with poor prognostic factors. In addition, a cut‐off value of HE4 was defined to classify patients according to these results.
Methods
Prospective and multicenter cohort analytical pilot study of patients operated for endometrial cancer at the Miguel Servet University Hospital of Zaragoza (Spain) and the Complejo Universitario of León (Spain) from January 2017 to May 2019. Preoperative serum levels of HE4 were analyzed by clinical and pathologic characteristics.
Results
In all, 126 patients were included. A statistically significant association was found between the preoperative HE4 value and node involvement (P = 0.008), late‐stage disease (P = 0.003), high histologic grade (P = 0.007), deep myometrial invasion (P = 0.001), lymphovascular space invasion (P = 0.001), and other pathologic factors. In addition, an HE4 cut‐off value (156.4 pmol/L) has been determined to predict, preoperatively, which patients will present with early stage disease.
Conclusions
The preoperative marker HE4 is a useful tool in the preoperative study of patients with endometrial cancer as it relates to late‐stage disease as well as other prognostic factors in the endometrioid subtype of endometrial cancer.
High preoperative values of HE4, especially higher than 156.4 pmol/L, seem to be associated with an advanced stage of disease in endometrioid endometrial cancer.</description><identifier>ISSN: 0020-7292</identifier><identifier>EISSN: 1879-3479</identifier><identifier>DOI: 10.1002/ijgo.13473</identifier><identifier>PMID: 33156532</identifier><language>eng</language><publisher>United States</publisher><subject>Advanced stage ; Aged ; Biomarkers, Tumor - blood ; Carcinoma, Endometrioid - pathology ; Cohort Studies ; Endometrial cancer ; Endometrial Neoplasms - pathology ; Endometrioid ; Female ; HE4 ; Humans ; Lymph node metastasis ; Middle Aged ; Pilot Projects ; Preoperative procedure ; Prognosis ; Prospective Studies ; Spain ; Tumoral markers ; WAP Four-Disulfide Core Domain Protein 2 - metabolism</subject><ispartof>International journal of gynecology and obstetrics, 2021-04, Vol.153 (1), p.64-70</ispartof><rights>2020 International Federation of Gynecology and Obstetrics</rights><rights>2020 International Federation of Gynecology and Obstetrics.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3293-1350736089d60e22b90954c01a0b1a362e7ee7164fce6fbcda88594de1602bdc3</citedby><cites>FETCH-LOGICAL-c3293-1350736089d60e22b90954c01a0b1a362e7ee7164fce6fbcda88594de1602bdc3</cites><orcidid>0000-0003-0357-2015 ; 0000-0002-8921-0682 ; 0000-0002-1060-9050 ; 0000-0003-2047-8995 ; 0000-0001-7184-2529 ; 0000-0002-1742-5617</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fijgo.13473$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fijgo.13473$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33156532$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Espiau Romera, Andrea</creatorcontrib><creatorcontrib>Coronado Martín, Pluvio Jesús</creatorcontrib><creatorcontrib>Chóliz Ezquerro, Marta</creatorcontrib><creatorcontrib>Cuesta Guardiola, Tatiana</creatorcontrib><creatorcontrib>Adiego Calvo, Ignacio</creatorcontrib><creatorcontrib>Baquedano Mainar, Laura</creatorcontrib><title>Value of preoperative HE4 as predictor of advanced disease in endometrioid endometrial cancer</title><title>International journal of gynecology and obstetrics</title><addtitle>Int J Gynaecol Obstet</addtitle><description>ABSTRACT
Objective
To explore the predictive value of serum human epididymis protein 4 (HE4) marker in the preoperative prediction of the risk of advanced disease in the endometrioid subtype of endometrial cancer, and its association with poor prognostic factors. In addition, a cut‐off value of HE4 was defined to classify patients according to these results.
Methods
Prospective and multicenter cohort analytical pilot study of patients operated for endometrial cancer at the Miguel Servet University Hospital of Zaragoza (Spain) and the Complejo Universitario of León (Spain) from January 2017 to May 2019. Preoperative serum levels of HE4 were analyzed by clinical and pathologic characteristics.
Results
In all, 126 patients were included. A statistically significant association was found between the preoperative HE4 value and node involvement (P = 0.008), late‐stage disease (P = 0.003), high histologic grade (P = 0.007), deep myometrial invasion (P = 0.001), lymphovascular space invasion (P = 0.001), and other pathologic factors. In addition, an HE4 cut‐off value (156.4 pmol/L) has been determined to predict, preoperatively, which patients will present with early stage disease.
Conclusions
The preoperative marker HE4 is a useful tool in the preoperative study of patients with endometrial cancer as it relates to late‐stage disease as well as other prognostic factors in the endometrioid subtype of endometrial cancer.
High preoperative values of HE4, especially higher than 156.4 pmol/L, seem to be associated with an advanced stage of disease in endometrioid endometrial cancer.</description><subject>Advanced stage</subject><subject>Aged</subject><subject>Biomarkers, Tumor - blood</subject><subject>Carcinoma, Endometrioid - pathology</subject><subject>Cohort Studies</subject><subject>Endometrial cancer</subject><subject>Endometrial Neoplasms - pathology</subject><subject>Endometrioid</subject><subject>Female</subject><subject>HE4</subject><subject>Humans</subject><subject>Lymph node metastasis</subject><subject>Middle Aged</subject><subject>Pilot Projects</subject><subject>Preoperative procedure</subject><subject>Prognosis</subject><subject>Prospective Studies</subject><subject>Spain</subject><subject>Tumoral markers</subject><subject>WAP Four-Disulfide Core Domain Protein 2 - metabolism</subject><issn>0020-7292</issn><issn>1879-3479</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kD1PwzAQQC0EoqWw8ANQRoSU4rPzOaKqtEWVugAbihz7glwlcbDTov57ElJgYzrf-ekNj5BroFOglN3r7buZAg9ifkLGkMSp373TUzLuPqkfs5SNyIVzW0opxADnZMQ5hFHI2Zi8vYpyh54pvMaiadCKVu_RW84DT7j-prRsje0Bofailqg8pR0Kh56uPayVqbC12mj1t4jSkz1qL8lZIUqHV8c5IS-P8-fZ0l9vFqvZw9qXnKXcBx7SmEc0SVVEkbE8pWkYSAqC5iB4xDBGjCEKColRkUslkiRMA4UQUZYrySfkdvA21nzs0LVZpZ3EshQ1mp3LWBAmtPMAdOjdgEprnLNYZI3VlbCHDGjW58z6nNl3zg6-OXp3eYXqF_3p1wEwAJ-6xMM_qmz1tNgM0i9SBn-t</recordid><startdate>202104</startdate><enddate>202104</enddate><creator>Espiau Romera, Andrea</creator><creator>Coronado Martín, Pluvio Jesús</creator><creator>Chóliz Ezquerro, Marta</creator><creator>Cuesta Guardiola, Tatiana</creator><creator>Adiego Calvo, Ignacio</creator><creator>Baquedano Mainar, Laura</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-0357-2015</orcidid><orcidid>https://orcid.org/0000-0002-8921-0682</orcidid><orcidid>https://orcid.org/0000-0002-1060-9050</orcidid><orcidid>https://orcid.org/0000-0003-2047-8995</orcidid><orcidid>https://orcid.org/0000-0001-7184-2529</orcidid><orcidid>https://orcid.org/0000-0002-1742-5617</orcidid></search><sort><creationdate>202104</creationdate><title>Value of preoperative HE4 as predictor of advanced disease in endometrioid endometrial cancer</title><author>Espiau Romera, Andrea ; Coronado Martín, Pluvio Jesús ; Chóliz Ezquerro, Marta ; Cuesta Guardiola, Tatiana ; Adiego Calvo, Ignacio ; Baquedano Mainar, Laura</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3293-1350736089d60e22b90954c01a0b1a362e7ee7164fce6fbcda88594de1602bdc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Advanced stage</topic><topic>Aged</topic><topic>Biomarkers, Tumor - blood</topic><topic>Carcinoma, Endometrioid - pathology</topic><topic>Cohort Studies</topic><topic>Endometrial cancer</topic><topic>Endometrial Neoplasms - pathology</topic><topic>Endometrioid</topic><topic>Female</topic><topic>HE4</topic><topic>Humans</topic><topic>Lymph node metastasis</topic><topic>Middle Aged</topic><topic>Pilot Projects</topic><topic>Preoperative procedure</topic><topic>Prognosis</topic><topic>Prospective Studies</topic><topic>Spain</topic><topic>Tumoral markers</topic><topic>WAP Four-Disulfide Core Domain Protein 2 - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Espiau Romera, Andrea</creatorcontrib><creatorcontrib>Coronado Martín, Pluvio Jesús</creatorcontrib><creatorcontrib>Chóliz Ezquerro, Marta</creatorcontrib><creatorcontrib>Cuesta Guardiola, Tatiana</creatorcontrib><creatorcontrib>Adiego Calvo, Ignacio</creatorcontrib><creatorcontrib>Baquedano Mainar, Laura</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of gynecology and obstetrics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Espiau Romera, Andrea</au><au>Coronado Martín, Pluvio Jesús</au><au>Chóliz Ezquerro, Marta</au><au>Cuesta Guardiola, Tatiana</au><au>Adiego Calvo, Ignacio</au><au>Baquedano Mainar, Laura</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Value of preoperative HE4 as predictor of advanced disease in endometrioid endometrial cancer</atitle><jtitle>International journal of gynecology and obstetrics</jtitle><addtitle>Int J Gynaecol Obstet</addtitle><date>2021-04</date><risdate>2021</risdate><volume>153</volume><issue>1</issue><spage>64</spage><epage>70</epage><pages>64-70</pages><issn>0020-7292</issn><eissn>1879-3479</eissn><abstract>ABSTRACT
Objective
To explore the predictive value of serum human epididymis protein 4 (HE4) marker in the preoperative prediction of the risk of advanced disease in the endometrioid subtype of endometrial cancer, and its association with poor prognostic factors. In addition, a cut‐off value of HE4 was defined to classify patients according to these results.
Methods
Prospective and multicenter cohort analytical pilot study of patients operated for endometrial cancer at the Miguel Servet University Hospital of Zaragoza (Spain) and the Complejo Universitario of León (Spain) from January 2017 to May 2019. Preoperative serum levels of HE4 were analyzed by clinical and pathologic characteristics.
Results
In all, 126 patients were included. A statistically significant association was found between the preoperative HE4 value and node involvement (P = 0.008), late‐stage disease (P = 0.003), high histologic grade (P = 0.007), deep myometrial invasion (P = 0.001), lymphovascular space invasion (P = 0.001), and other pathologic factors. In addition, an HE4 cut‐off value (156.4 pmol/L) has been determined to predict, preoperatively, which patients will present with early stage disease.
Conclusions
The preoperative marker HE4 is a useful tool in the preoperative study of patients with endometrial cancer as it relates to late‐stage disease as well as other prognostic factors in the endometrioid subtype of endometrial cancer.
High preoperative values of HE4, especially higher than 156.4 pmol/L, seem to be associated with an advanced stage of disease in endometrioid endometrial cancer.</abstract><cop>United States</cop><pmid>33156532</pmid><doi>10.1002/ijgo.13473</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0003-0357-2015</orcidid><orcidid>https://orcid.org/0000-0002-8921-0682</orcidid><orcidid>https://orcid.org/0000-0002-1060-9050</orcidid><orcidid>https://orcid.org/0000-0003-2047-8995</orcidid><orcidid>https://orcid.org/0000-0001-7184-2529</orcidid><orcidid>https://orcid.org/0000-0002-1742-5617</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0020-7292 |
| ispartof | International journal of gynecology and obstetrics, 2021-04, Vol.153 (1), p.64-70 |
| issn | 0020-7292 1879-3479 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2458036211 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | Advanced stage Aged Biomarkers, Tumor - blood Carcinoma, Endometrioid - pathology Cohort Studies Endometrial cancer Endometrial Neoplasms - pathology Endometrioid Female HE4 Humans Lymph node metastasis Middle Aged Pilot Projects Preoperative procedure Prognosis Prospective Studies Spain Tumoral markers WAP Four-Disulfide Core Domain Protein 2 - metabolism |
| title | Value of preoperative HE4 as predictor of advanced disease in endometrioid endometrial cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T05%3A53%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Value%20of%20preoperative%20HE4%20as%20predictor%20of%20advanced%20disease%20in%20endometrioid%20endometrial%20cancer&rft.jtitle=International%20journal%20of%20gynecology%20and%20obstetrics&rft.au=Espiau%20Romera,%20Andrea&rft.date=2021-04&rft.volume=153&rft.issue=1&rft.spage=64&rft.epage=70&rft.pages=64-70&rft.issn=0020-7292&rft.eissn=1879-3479&rft_id=info:doi/10.1002/ijgo.13473&rft_dat=%3Cproquest_cross%3E2458036211%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2458036211&rft_id=info:pmid/33156532&rfr_iscdi=true |